Herein, we report for the first time of the novel vaccine cell composed with allogenic mature dendritic cells (DCs) and inactive gastric cancer (GC) cells prepared by PEG mediated fusion. Combined with effecter of cytokine induced killing cells (CIKs), the immunotherapeutic and prophylactic potential of the fused vaccine cells (VCs) were evaluated in tumor-bearing, post-surgery and tumor free mice models. The migration and homing process of near infrared region quantum dots (NIR-QDs) labeled VCs were investigated by real-time animal imaging system. Results showed that the VCs and VC+CIKs could trigger the tumor-specific CTLs against GC cell, target the tumor tissue initiatively and enhance the prophylactic effects, suppress the tumor growth remarkably in vivo. The potential mechanism is also investigated. In conclusion, the novel vaccine cells can be used for targeted imaging and enhanced immunotherapeutic efficacy of GC, and hopeful to solve the double problems of antigen delivery and host immunity enhancement at the same time.
Gastric cancer (GC) is the third leading cause of cancer death in both sexes worldwide [1, 2] . It has been proven that, the traditional therapeutic strategies, including surgery, chemotherapy and radiotherapy are not effective enough to eradicate GC cell thoroughly, metastasis and recurrence are the major causes of death. The reasons leading to this situation can be summarized as following: (I) The intrinsic antigenicity weakness of tumor cells [3, 4] , immunological surveillance of the host can not identify and eliminate the malignant cells exactly. (II) Immunological surveillance defect or dysfunction of the host. (III) Most of the traditional curative intents often compromised by the extreme feeble immunity of the patient. Therefore, it is very necessary to develop new therapeutic strategies that could enhance the host immunosurveilliance and/or improve immunogenicity of the tumor cell.
Dendritic cell (DC) is the native antigen-presenting cell of immune system. It can capture, process and present the "foreign" antigen to effecter cells, launch the immune response to against the foreign "intruder's" aggression [5] . DCs provide an essential link between the immunological memory and adaptive immune responses [6] . Consequently, DCs and the tumor antigen conjugation hybrids (DC-based vaccines) can be an ideal candidate for the immunogenicity of tumor cells to boost anti-tumor response in host [7, 8] . Far
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from antigen present, the DC-based vaccines could also enhance the host immunity and compensate for the natural immunogenic weaknesses of tumor cells.
Compared with protein or DNA based DCs-vaccines [9] , the new generation vaccine of DCs fused with tumor cell could avoid the complicated purification process of tumor specific antigen or DNA, the inactive tumor cells could be used for vaccine production directly without tumorigenic risk. Furthermore, either tumor-specific antigens (TSA) or tumor-associated antigens (TAA) is not fully representative of whole antigen of tumor cells, the immunogenicity triggered by these vaccines will be restricted to a relative narrow range [10] [11] [12] . With the repertoire of whole tumor antigens, the DCs-tumor vaccine can induce the production of various antigenic determinants of cytotoxic T lymphocyte (CTL) clones and elicit effective cytotoxicity to antagonise tumor cells completely [13] . Given the central role in actuation cell-mediated immunity, the fused vaccine cells (VCs) of DCs-tumor cell hybrids hold much promise in cancer prophylaxis and therapy [14] . CuInS2 (CIS) is a I-III-VI2 semiconductor quantum dots (QDs) with wide range of photoluminescence (PL) and good biocompatibility [15] [16] [17] . Because of near infrared region (NIR) light owns favorable deep penetration and low photodamage to biological tissues [17, 18] , the NIR-QDs can be a promising candidate as a tracer for visualizing the distribution of individual VCs in host tissues/organs and therefore, the NIR-QDs can be used to investigate the biodistribution and the potential mechanism of immunotherapy and immunoprophylaxis of vaccine.
In experiment, the mononuclear cells were extracted from the peripheral blood of healthy donors. The CIKs and DCs were generated following standard procedure and characterized by FACS Calibur. For VCs preparation, the matured DCs and inactive MGC-803 cell were fused by polyethylene glycol (PEG) mediated fusion and cultured in DCs medium for 4~5 days [19, 20] . The suspended VCs and culture supernatant were collected respectively for following experiments. The CuInS2 /ZnS NIR-QDs were synthesized in organic solvent as the previous report with some minor modifications, and transferred to hydrophilic phase with DSPE-PEG. The monoclonal antibody (Mab) NIR-QDs probes were synthesized with carbodiimide chemistry as the previous reports [21] and the label efficiency was evaluated by Bruker In-Vivo F PRO system. In addition, the morphology and structure of the synthesized VCs were characterized by confocal microscope, TEM, SEM, Giemsa and HE staining. In order to evaluate the immunotheraputic effectiveness and biodistribution in vivo of the prepared VCs, the NIR-QDs labeled VCs were vaccinated C57BL/6 mice, including tumor-bear group, post-surgery group, tumor-free group and control group (without vaccinated).
The confocal image showed that almost every VC cell was composited with a tumor cell and at least 3~ DCs cells. The SEM and the TEM images of VCs confirmed that the cytomembrane and cytoplast of the two parent cells had fused together. In addition, the HE and Giemsa stain of VCs also presented multinucleated appearance. These results demonstrated that the whole tumor antigen have been engrafted to DCs' surface successfully (as showed in Fig. 1 ).
After vaccination, over 10 or 20 days, the tumor volume became shrink and reached to the level of hardly can be measured in tumor-bear group, and in control group, the tumor volume exhibited a significant increase with time elapsed from tumor implant. In post-surgery group, virtually no palpable tumor growth was observed. Furthermore, after vaccination, the tumor-free group mice can endure 2×10 6 cancer cell challenge without detectable tumor generation and the Kaplan-Meier curve of these groups also showed the vaccination with VCs could evidently improve survival rate compared with that of control group. These results demonstrated the VCs administration enhanced the immunotherapeutic efficacy significantly and prevented the tumor recurrence of post-operation obviously. In order to trace the biodistrbution of VCs and CIKs, the VCs and CIKs were labeled with Mab NIR-QDs probes and transplanted to the tumor-bear mice via tail vein. With time elapsed after the CIKs and VCs transplantation, the NIR fluorescence signals were mainly accumulated in tumor sites, and the strongest signal can be detected in Bruker system at the 5 th and 7 th days for CIKs and VCs respectively. In addition, in vivo histological and cytokine variation in different groups also confirm the application of VCs enhanced the Th1 immunity and decreased Th2 immunity, improved the ratio of Th1/Th2 [22] , which contribute to the enhanced anti-tumor immune responses. In another experiment, the concentration of serum IL-7 and IL-15 were also tested between different groups, the VCs+CIKs owned the highest level of IL-7 and IL-15, which are the primary cytokines produced by the cancer immunity and immune memory cells of CD4+ and CD8+ T cells. Just because of the VCs carried the full tumor antigens that triggered the tumor histological changes, the variations of cytokine level and the long term immune memory in vivo, the infusion of VCs or VC+CIKs could inhibited the tumor growth, prolonged the median survive efficiently.
Overall, we have provided an effective strategy to prepare DCs based tumor vaccines that contained the full tumor antigens, and verified the antigen presenting and tumor targeting effect in vivo. Our results demonstrated that the VCs can act as efficient vehicles to deliver tumor antigen systemically, activate the CTL effects and trigger the intensive antitumor immune response. Our research provides a new insight into the immunobiology of tumor-associated vaccines and hopeful to solve the double problems of antigen delivery and host immunity enhancement at the same time.
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